Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Recombinant Coagulation Factors Market by Product Type (Recombinant Factor VIII, Recombinant Factor IX, Von Willebrand Factor), by Hemophilia Type (Hemophilia A, Hemophilia B) and by End User (Hospitals, Clinics, Research Organizations): Global Opportunity Analysis and Industry Forecast, 2023-2032

A02925

Pages: NA

Charts: NA

Tables: NA

Recombinant coagulation factors are plasma derived counterparts used to treat infection from viruses such as hepatitis C and the human immunodeficiency virus. In addition, recombinant coagulation factors have low risk for transmission of infectious agents.

Increase in number of hemophilia patients and rise in number of R&D on coagulation factors drive the market. However, high cost associated with hemophilia treatment and availability of alternative recombinant coagulation factors impede the market growth. Moreover, the expansion of the business in developing economies such as China, India, and Brazil create more lucrative opportunities for the market.

The global recombinant coagulation factors market is segmented based on product type, hemophilia type, end user, and geography. Based on product type, the market is classified into recombinant factor VIII, recombinant factor IX, and Von Willebrand factor. Based on hemophilia type, the market is divided into hemophilia A and hemophilia B. Based on end user, it is categorized into hospitals, clinics, and research organizations. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Comprehensive competitive analysis and profiles of major market players such as Baxter International Inc., Bayer AG, Biogen Idec, CSL Ltd., Grifols International SA, Kedrion S.P.A., Novo Nordisk A/S, Octapharma AG, and Pfizer Inc. are also provided in this report.

Key Benefits

  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the global recombinant coagulation factors market.
  • In-depth analysis is conducted by constructing market estimations for the key market segments.
  • This study evaluating competitive landscape and value chain is taken into account to help understand the competitive environment across the geographies.
  • Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
  • This report provides the quantitative analysis of the current market and estimations which assists in identifying the prevailing market opportunities
  • Comprehensive analysis of all regions are provided that determines the prevailing opportunities in these geographies.

 Key Market Segments

  • By Product Type
    • Recombinant Factor VIII
    • Recombinant Factor IX
    • Von Willebrand Factor
  • By Hemophilia Type
    • Hemophilia A
    • Hemophilia B
  • By End User
    • Hospitals
    • Clinics
    • Research Organizations
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Kedrion S.P.A.
  • Pfizer Inc.
  • Novo Nordisk A/S
  • Bayer AG
  • Grifols International SA
  • Biogen Idec
  • Baxter International Inc.
  • CSL Ltd.
  • Octapharma AG

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: RECOMBINANT COAGULATION FACTORS MARKET, BY PRODUCT TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product Type

    • 4.2. Recombinant Factor VIII

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Recombinant Factor IX

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Von Willebrand Factor

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: RECOMBINANT COAGULATION FACTORS MARKET, BY HEMOPHILIA TYPE

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Hemophilia Type

    • 5.2. Hemophilia A

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Hemophilia B

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: RECOMBINANT COAGULATION FACTORS MARKET, BY END USER

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End User

    • 6.2. Hospitals

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Clinics

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Research Organizations

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: RECOMBINANT COAGULATION FACTORS MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Product Type

      • 7.2.3. Market Size and Forecast, By Hemophilia Type

      • 7.2.4. Market Size and Forecast, By End User

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Recombinant Coagulation Factors Market

        • 7.2.6.1. Market Size and Forecast, By Product Type
        • 7.2.6.2. Market Size and Forecast, By Hemophilia Type
        • 7.2.6.3. Market Size and Forecast, By End User

      • 7.2.7. Canada Recombinant Coagulation Factors Market

        • 7.2.7.1. Market Size and Forecast, By Product Type
        • 7.2.7.2. Market Size and Forecast, By Hemophilia Type
        • 7.2.7.3. Market Size and Forecast, By End User

      • 7.2.8. Mexico Recombinant Coagulation Factors Market

        • 7.2.8.1. Market Size and Forecast, By Product Type
        • 7.2.8.2. Market Size and Forecast, By Hemophilia Type
        • 7.2.8.3. Market Size and Forecast, By End User

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Product Type

      • 7.3.3. Market Size and Forecast, By Hemophilia Type

      • 7.3.4. Market Size and Forecast, By End User

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Recombinant Coagulation Factors Market

        • 7.3.6.1. Market Size and Forecast, By Product Type
        • 7.3.6.2. Market Size and Forecast, By Hemophilia Type
        • 7.3.6.3. Market Size and Forecast, By End User

      • 7.3.7. Germany Recombinant Coagulation Factors Market

        • 7.3.7.1. Market Size and Forecast, By Product Type
        • 7.3.7.2. Market Size and Forecast, By Hemophilia Type
        • 7.3.7.3. Market Size and Forecast, By End User

      • 7.3.8. Italy Recombinant Coagulation Factors Market

        • 7.3.8.1. Market Size and Forecast, By Product Type
        • 7.3.8.2. Market Size and Forecast, By Hemophilia Type
        • 7.3.8.3. Market Size and Forecast, By End User

      • 7.3.9. Spain Recombinant Coagulation Factors Market

        • 7.3.9.1. Market Size and Forecast, By Product Type
        • 7.3.9.2. Market Size and Forecast, By Hemophilia Type
        • 7.3.9.3. Market Size and Forecast, By End User

      • 7.3.10. UK Recombinant Coagulation Factors Market

        • 7.3.10.1. Market Size and Forecast, By Product Type
        • 7.3.10.2. Market Size and Forecast, By Hemophilia Type
        • 7.3.10.3. Market Size and Forecast, By End User

      • 7.3.11. Russia Recombinant Coagulation Factors Market

        • 7.3.11.1. Market Size and Forecast, By Product Type
        • 7.3.11.2. Market Size and Forecast, By Hemophilia Type
        • 7.3.11.3. Market Size and Forecast, By End User

      • 7.3.12. Rest Of Europe Recombinant Coagulation Factors Market

        • 7.3.12.1. Market Size and Forecast, By Product Type
        • 7.3.12.2. Market Size and Forecast, By Hemophilia Type
        • 7.3.12.3. Market Size and Forecast, By End User

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Product Type

      • 7.4.3. Market Size and Forecast, By Hemophilia Type

      • 7.4.4. Market Size and Forecast, By End User

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Recombinant Coagulation Factors Market

        • 7.4.6.1. Market Size and Forecast, By Product Type
        • 7.4.6.2. Market Size and Forecast, By Hemophilia Type
        • 7.4.6.3. Market Size and Forecast, By End User

      • 7.4.7. Japan Recombinant Coagulation Factors Market

        • 7.4.7.1. Market Size and Forecast, By Product Type
        • 7.4.7.2. Market Size and Forecast, By Hemophilia Type
        • 7.4.7.3. Market Size and Forecast, By End User

      • 7.4.8. India Recombinant Coagulation Factors Market

        • 7.4.8.1. Market Size and Forecast, By Product Type
        • 7.4.8.2. Market Size and Forecast, By Hemophilia Type
        • 7.4.8.3. Market Size and Forecast, By End User

      • 7.4.9. South Korea Recombinant Coagulation Factors Market

        • 7.4.9.1. Market Size and Forecast, By Product Type
        • 7.4.9.2. Market Size and Forecast, By Hemophilia Type
        • 7.4.9.3. Market Size and Forecast, By End User

      • 7.4.10. Australia Recombinant Coagulation Factors Market

        • 7.4.10.1. Market Size and Forecast, By Product Type
        • 7.4.10.2. Market Size and Forecast, By Hemophilia Type
        • 7.4.10.3. Market Size and Forecast, By End User

      • 7.4.11. Thailand Recombinant Coagulation Factors Market

        • 7.4.11.1. Market Size and Forecast, By Product Type
        • 7.4.11.2. Market Size and Forecast, By Hemophilia Type
        • 7.4.11.3. Market Size and Forecast, By End User

      • 7.4.12. Malaysia Recombinant Coagulation Factors Market

        • 7.4.12.1. Market Size and Forecast, By Product Type
        • 7.4.12.2. Market Size and Forecast, By Hemophilia Type
        • 7.4.12.3. Market Size and Forecast, By End User

      • 7.4.13. Indonesia Recombinant Coagulation Factors Market

        • 7.4.13.1. Market Size and Forecast, By Product Type
        • 7.4.13.2. Market Size and Forecast, By Hemophilia Type
        • 7.4.13.3. Market Size and Forecast, By End User

      • 7.4.14. Rest of Asia Pacific Recombinant Coagulation Factors Market

        • 7.4.14.1. Market Size and Forecast, By Product Type
        • 7.4.14.2. Market Size and Forecast, By Hemophilia Type
        • 7.4.14.3. Market Size and Forecast, By End User

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Product Type

      • 7.5.3. Market Size and Forecast, By Hemophilia Type

      • 7.5.4. Market Size and Forecast, By End User

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Recombinant Coagulation Factors Market

        • 7.5.6.1. Market Size and Forecast, By Product Type
        • 7.5.6.2. Market Size and Forecast, By Hemophilia Type
        • 7.5.6.3. Market Size and Forecast, By End User

      • 7.5.7. South Africa Recombinant Coagulation Factors Market

        • 7.5.7.1. Market Size and Forecast, By Product Type
        • 7.5.7.2. Market Size and Forecast, By Hemophilia Type
        • 7.5.7.3. Market Size and Forecast, By End User

      • 7.5.8. Saudi Arabia Recombinant Coagulation Factors Market

        • 7.5.8.1. Market Size and Forecast, By Product Type
        • 7.5.8.2. Market Size and Forecast, By Hemophilia Type
        • 7.5.8.3. Market Size and Forecast, By End User

      • 7.5.9. UAE Recombinant Coagulation Factors Market

        • 7.5.9.1. Market Size and Forecast, By Product Type
        • 7.5.9.2. Market Size and Forecast, By Hemophilia Type
        • 7.5.9.3. Market Size and Forecast, By End User

      • 7.5.10. Argentina Recombinant Coagulation Factors Market

        • 7.5.10.1. Market Size and Forecast, By Product Type
        • 7.5.10.2. Market Size and Forecast, By Hemophilia Type
        • 7.5.10.3. Market Size and Forecast, By End User

      • 7.5.11. Rest of LAMEA Recombinant Coagulation Factors Market

        • 7.5.11.1. Market Size and Forecast, By Product Type
        • 7.5.11.2. Market Size and Forecast, By Hemophilia Type
        • 7.5.11.3. Market Size and Forecast, By End User

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Baxter International Inc.

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Bayer AG

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Biogen Idec

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. CSL Ltd.

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Grifols International SA

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Kedrion S.P.A.

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Novo Nordisk A/S

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Octapharma AG

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Pfizer Inc.

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL RECOMBINANT COAGULATION FACTORS MARKET, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL RECOMBINANT COAGULATION FACTORS MARKET FOR RECOMBINANT FACTOR VIII, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL RECOMBINANT COAGULATION FACTORS MARKET FOR RECOMBINANT FACTOR IX, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL RECOMBINANT COAGULATION FACTORS MARKET FOR VON WILLEBRAND FACTOR, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL RECOMBINANT COAGULATION FACTORS MARKET, BY HEMOPHILIA TYPE, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL RECOMBINANT COAGULATION FACTORS MARKET FOR HEMOPHILIA A, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL RECOMBINANT COAGULATION FACTORS MARKET FOR HEMOPHILIA B, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL RECOMBINANT COAGULATION FACTORS MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL RECOMBINANT COAGULATION FACTORS MARKET FOR HOSPITALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL RECOMBINANT COAGULATION FACTORS MARKET FOR CLINICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL RECOMBINANT COAGULATION FACTORS MARKET FOR RESEARCH ORGANIZATIONS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL RECOMBINANT COAGULATION FACTORS MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. NORTH AMERICA RECOMBINANT COAGULATION FACTORS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. NORTH AMERICA RECOMBINANT COAGULATION FACTORS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 15. NORTH AMERICA RECOMBINANT COAGULATION FACTORS, BY HEMOPHILIA TYPE, 2025-2033 ($MILLION)
  • TABLE 16. NORTH AMERICA RECOMBINANT COAGULATION FACTORS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 17. U.S. RECOMBINANT COAGULATION FACTORS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 18. U.S. RECOMBINANT COAGULATION FACTORS, BY HEMOPHILIA TYPE, 2025-2033 ($MILLION)
  • TABLE 19. U.S. RECOMBINANT COAGULATION FACTORS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 20. CANADA RECOMBINANT COAGULATION FACTORS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 21. CANADA RECOMBINANT COAGULATION FACTORS, BY HEMOPHILIA TYPE, 2025-2033 ($MILLION)
  • TABLE 22. CANADA RECOMBINANT COAGULATION FACTORS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 23. MEXICO RECOMBINANT COAGULATION FACTORS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 24. MEXICO RECOMBINANT COAGULATION FACTORS, BY HEMOPHILIA TYPE, 2025-2033 ($MILLION)
  • TABLE 25. MEXICO RECOMBINANT COAGULATION FACTORS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 26. EUROPE RECOMBINANT COAGULATION FACTORS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 27. EUROPE RECOMBINANT COAGULATION FACTORS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 28. EUROPE RECOMBINANT COAGULATION FACTORS, BY HEMOPHILIA TYPE, 2025-2033 ($MILLION)
  • TABLE 29. EUROPE RECOMBINANT COAGULATION FACTORS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 30. FRANCE RECOMBINANT COAGULATION FACTORS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 31. FRANCE RECOMBINANT COAGULATION FACTORS, BY HEMOPHILIA TYPE, 2025-2033 ($MILLION)
  • TABLE 32. FRANCE RECOMBINANT COAGULATION FACTORS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 33. GERMANY RECOMBINANT COAGULATION FACTORS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 34. GERMANY RECOMBINANT COAGULATION FACTORS, BY HEMOPHILIA TYPE, 2025-2033 ($MILLION)
  • TABLE 35. GERMANY RECOMBINANT COAGULATION FACTORS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 36. ITALY RECOMBINANT COAGULATION FACTORS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 37. ITALY RECOMBINANT COAGULATION FACTORS, BY HEMOPHILIA TYPE, 2025-2033 ($MILLION)
  • TABLE 38. ITALY RECOMBINANT COAGULATION FACTORS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 39. SPAIN RECOMBINANT COAGULATION FACTORS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 40. SPAIN RECOMBINANT COAGULATION FACTORS, BY HEMOPHILIA TYPE, 2025-2033 ($MILLION)
  • TABLE 41. SPAIN RECOMBINANT COAGULATION FACTORS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 42. UK RECOMBINANT COAGULATION FACTORS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 43. UK RECOMBINANT COAGULATION FACTORS, BY HEMOPHILIA TYPE, 2025-2033 ($MILLION)
  • TABLE 44. UK RECOMBINANT COAGULATION FACTORS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 45. RUSSIA RECOMBINANT COAGULATION FACTORS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 46. RUSSIA RECOMBINANT COAGULATION FACTORS, BY HEMOPHILIA TYPE, 2025-2033 ($MILLION)
  • TABLE 47. RUSSIA RECOMBINANT COAGULATION FACTORS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 48. REST OF EUROPE RECOMBINANT COAGULATION FACTORS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 49. REST OF EUROPE RECOMBINANT COAGULATION FACTORS, BY HEMOPHILIA TYPE, 2025-2033 ($MILLION)
  • TABLE 50. REST OF EUROPE RECOMBINANT COAGULATION FACTORS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 51. ASIA-PACIFIC RECOMBINANT COAGULATION FACTORS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 52. ASIA-PACIFIC RECOMBINANT COAGULATION FACTORS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 53. ASIA-PACIFIC RECOMBINANT COAGULATION FACTORS, BY HEMOPHILIA TYPE, 2025-2033 ($MILLION)
  • TABLE 54. ASIA-PACIFIC RECOMBINANT COAGULATION FACTORS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 55. CHINA RECOMBINANT COAGULATION FACTORS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 56. CHINA RECOMBINANT COAGULATION FACTORS, BY HEMOPHILIA TYPE, 2025-2033 ($MILLION)
  • TABLE 57. CHINA RECOMBINANT COAGULATION FACTORS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 58. JAPAN RECOMBINANT COAGULATION FACTORS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 59. JAPAN RECOMBINANT COAGULATION FACTORS, BY HEMOPHILIA TYPE, 2025-2033 ($MILLION)
  • TABLE 60. JAPAN RECOMBINANT COAGULATION FACTORS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 61. INDIA RECOMBINANT COAGULATION FACTORS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 62. INDIA RECOMBINANT COAGULATION FACTORS, BY HEMOPHILIA TYPE, 2025-2033 ($MILLION)
  • TABLE 63. INDIA RECOMBINANT COAGULATION FACTORS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 64. SOUTH KOREA RECOMBINANT COAGULATION FACTORS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 65. SOUTH KOREA RECOMBINANT COAGULATION FACTORS, BY HEMOPHILIA TYPE, 2025-2033 ($MILLION)
  • TABLE 66. SOUTH KOREA RECOMBINANT COAGULATION FACTORS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 67. AUSTRALIA RECOMBINANT COAGULATION FACTORS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 68. AUSTRALIA RECOMBINANT COAGULATION FACTORS, BY HEMOPHILIA TYPE, 2025-2033 ($MILLION)
  • TABLE 69. AUSTRALIA RECOMBINANT COAGULATION FACTORS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 70. THAILAND RECOMBINANT COAGULATION FACTORS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 71. THAILAND RECOMBINANT COAGULATION FACTORS, BY HEMOPHILIA TYPE, 2025-2033 ($MILLION)
  • TABLE 72. THAILAND RECOMBINANT COAGULATION FACTORS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 73. MALAYSIA RECOMBINANT COAGULATION FACTORS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 74. MALAYSIA RECOMBINANT COAGULATION FACTORS, BY HEMOPHILIA TYPE, 2025-2033 ($MILLION)
  • TABLE 75. MALAYSIA RECOMBINANT COAGULATION FACTORS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 76. INDONESIA RECOMBINANT COAGULATION FACTORS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 77. INDONESIA RECOMBINANT COAGULATION FACTORS, BY HEMOPHILIA TYPE, 2025-2033 ($MILLION)
  • TABLE 78. INDONESIA RECOMBINANT COAGULATION FACTORS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 79. REST OF ASIA PACIFIC RECOMBINANT COAGULATION FACTORS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 80. REST OF ASIA PACIFIC RECOMBINANT COAGULATION FACTORS, BY HEMOPHILIA TYPE, 2025-2033 ($MILLION)
  • TABLE 81. REST OF ASIA PACIFIC RECOMBINANT COAGULATION FACTORS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 82. LAMEA RECOMBINANT COAGULATION FACTORS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 83. LAMEA RECOMBINANT COAGULATION FACTORS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 84. LAMEA RECOMBINANT COAGULATION FACTORS, BY HEMOPHILIA TYPE, 2025-2033 ($MILLION)
  • TABLE 85. LAMEA RECOMBINANT COAGULATION FACTORS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 86. BRAZIL RECOMBINANT COAGULATION FACTORS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 87. BRAZIL RECOMBINANT COAGULATION FACTORS, BY HEMOPHILIA TYPE, 2025-2033 ($MILLION)
  • TABLE 88. BRAZIL RECOMBINANT COAGULATION FACTORS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 89. SOUTH AFRICA RECOMBINANT COAGULATION FACTORS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 90. SOUTH AFRICA RECOMBINANT COAGULATION FACTORS, BY HEMOPHILIA TYPE, 2025-2033 ($MILLION)
  • TABLE 91. SOUTH AFRICA RECOMBINANT COAGULATION FACTORS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 92. SAUDI ARABIA RECOMBINANT COAGULATION FACTORS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 93. SAUDI ARABIA RECOMBINANT COAGULATION FACTORS, BY HEMOPHILIA TYPE, 2025-2033 ($MILLION)
  • TABLE 94. SAUDI ARABIA RECOMBINANT COAGULATION FACTORS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 95. UAE RECOMBINANT COAGULATION FACTORS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 96. UAE RECOMBINANT COAGULATION FACTORS, BY HEMOPHILIA TYPE, 2025-2033 ($MILLION)
  • TABLE 97. UAE RECOMBINANT COAGULATION FACTORS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 98. ARGENTINA RECOMBINANT COAGULATION FACTORS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 99. ARGENTINA RECOMBINANT COAGULATION FACTORS, BY HEMOPHILIA TYPE, 2025-2033 ($MILLION)
  • TABLE 100. ARGENTINA RECOMBINANT COAGULATION FACTORS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 101. REST OF LAMEA RECOMBINANT COAGULATION FACTORS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 102. REST OF LAMEA RECOMBINANT COAGULATION FACTORS, BY HEMOPHILIA TYPE, 2025-2033 ($MILLION)
  • TABLE 103. REST OF LAMEA RECOMBINANT COAGULATION FACTORS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 104. BAXTER INTERNATIONAL INC.: KEY EXECUTIVES
  • TABLE 105. BAXTER INTERNATIONAL INC.: COMPANY SNAPSHOT
  • TABLE 106. BAXTER INTERNATIONAL INC.: OPERATING SEGMENTS
  • TABLE 107. BAXTER INTERNATIONAL INC.: PRODUCT PORTFOLIO
  • TABLE 108. BAXTER INTERNATIONAL INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 109. BAYER AG: KEY EXECUTIVES
  • TABLE 110. BAYER AG: COMPANY SNAPSHOT
  • TABLE 111. BAYER AG: OPERATING SEGMENTS
  • TABLE 112. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 113. BAYER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 114. BIOGEN IDEC: KEY EXECUTIVES
  • TABLE 115. BIOGEN IDEC: COMPANY SNAPSHOT
  • TABLE 116. BIOGEN IDEC: OPERATING SEGMENTS
  • TABLE 117. BIOGEN IDEC: PRODUCT PORTFOLIO
  • TABLE 118. BIOGEN IDEC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 119. CSL LTD.: KEY EXECUTIVES
  • TABLE 120. CSL LTD.: COMPANY SNAPSHOT
  • TABLE 121. CSL LTD.: OPERATING SEGMENTS
  • TABLE 122. CSL LTD.: PRODUCT PORTFOLIO
  • TABLE 123. CSL LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 124. GRIFOLS INTERNATIONAL SA: KEY EXECUTIVES
  • TABLE 125. GRIFOLS INTERNATIONAL SA: COMPANY SNAPSHOT
  • TABLE 126. GRIFOLS INTERNATIONAL SA: OPERATING SEGMENTS
  • TABLE 127. GRIFOLS INTERNATIONAL SA: PRODUCT PORTFOLIO
  • TABLE 128. GRIFOLS INTERNATIONAL SA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 129. KEDRION S.P.A.: KEY EXECUTIVES
  • TABLE 130. KEDRION S.P.A.: COMPANY SNAPSHOT
  • TABLE 131. KEDRION S.P.A.: OPERATING SEGMENTS
  • TABLE 132. KEDRION S.P.A.: PRODUCT PORTFOLIO
  • TABLE 133. KEDRION S.P.A.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 134. NOVO NORDISK A/S: KEY EXECUTIVES
  • TABLE 135. NOVO NORDISK A/S: COMPANY SNAPSHOT
  • TABLE 136. NOVO NORDISK A/S: OPERATING SEGMENTS
  • TABLE 137. NOVO NORDISK A/S: PRODUCT PORTFOLIO
  • TABLE 138. NOVO NORDISK A/S: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 139. OCTAPHARMA AG: KEY EXECUTIVES
  • TABLE 140. OCTAPHARMA AG: COMPANY SNAPSHOT
  • TABLE 141. OCTAPHARMA AG: OPERATING SEGMENTS
  • TABLE 142. OCTAPHARMA AG: PRODUCT PORTFOLIO
  • TABLE 143. OCTAPHARMA AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 144. PFIZER INC.: KEY EXECUTIVES
  • TABLE 145. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 146. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 147. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 148. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL RECOMBINANT COAGULATION FACTORS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL RECOMBINANT COAGULATION FACTORS MARKET
  • FIGURE 3. SEGMENTATION RECOMBINANT COAGULATION FACTORS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN RECOMBINANT COAGULATION FACTORS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALRECOMBINANT COAGULATION FACTORS MARKET
  • FIGURE 11. RECOMBINANT COAGULATION FACTORS MARKET SEGMENTATION, BY BY PRODUCT TYPE
  • FIGURE 12. RECOMBINANT COAGULATION FACTORS MARKET FOR RECOMBINANT FACTOR VIII, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. RECOMBINANT COAGULATION FACTORS MARKET FOR RECOMBINANT FACTOR IX, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. RECOMBINANT COAGULATION FACTORS MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. RECOMBINANT COAGULATION FACTORS MARKET SEGMENTATION, BY BY HEMOPHILIA TYPE
  • FIGURE 16. RECOMBINANT COAGULATION FACTORS MARKET FOR HEMOPHILIA A, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. RECOMBINANT COAGULATION FACTORS MARKET FOR HEMOPHILIA B, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. RECOMBINANT COAGULATION FACTORS MARKET SEGMENTATION, BY BY END USER
  • FIGURE 19. RECOMBINANT COAGULATION FACTORS MARKET FOR HOSPITALS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. RECOMBINANT COAGULATION FACTORS MARKET FOR CLINICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. RECOMBINANT COAGULATION FACTORS MARKET FOR RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 23. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 24. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 25. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 26. COMPETITIVE DASHBOARD
  • FIGURE 27. COMPETITIVE HEATMAP: RECOMBINANT COAGULATION FACTORS MARKET
  • FIGURE 28. TOP PLAYER POSITIONING, 2024
  • FIGURE 29. BAXTER INTERNATIONAL INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 30. BAXTER INTERNATIONAL INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 31. BAXTER INTERNATIONAL INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 32. BAYER AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 33. BAYER AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 34. BAYER AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 35. BIOGEN IDEC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 36. BIOGEN IDEC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 37. BIOGEN IDEC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 38. CSL LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 39. CSL LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 40. CSL LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 41. GRIFOLS INTERNATIONAL SA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 42. GRIFOLS INTERNATIONAL SA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 43. GRIFOLS INTERNATIONAL SA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 44. KEDRION S.P.A.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 45. KEDRION S.P.A.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 46. KEDRION S.P.A.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 47. NOVO NORDISK A/S: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 48. NOVO NORDISK A/S: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 49. NOVO NORDISK A/S: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 50. OCTAPHARMA AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 51. OCTAPHARMA AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 52. OCTAPHARMA AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 53. PFIZER INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 54. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 55. PFIZER INC.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Recombinant Coagulation Factors Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved